INS and chronic kidney disease: The AWARD-7 study, which compared dulaglutide and insulin glargine use, both combined with insulin lispro, in patients with T2D and stage 3 or 4 CKD found that the use of dulaglutide was associated with less eGFR decline at 26 weeks [41].